XML 30 R18.htm IDEA: XBRL DOCUMENT

Equity Incentive Plans (Tables)

3 Months Ended

Mar. 31, 2017

Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]

A summary of the status of the Company’s option plans as of March 31, 2017 and changes during the period then ended is presented below:

	Three months ended March 31, 2017
	Unaudited
	Number of options			Weighted average exercise price
Outstanding at beginning of year		11,377,354		$	9.76
Granted		2,640,500			7.15
Exercised		(427,191	)		0.17
Forfeited and cancelled		(47,699	)		18.01
Outstanding as of March 31, 2017		13,542,964			9.53

Exercisable options		6,644,144			7.25

Vested and expected to vest		13,542,964		$	9.53

Schedule of RSU's

A summary of the status of the Company’s RSUs as of March 31, 2017 and changes during the period then ended is presented below:

	Three months ended March 31, 2017
	Unaudited
	Number of RSU		Weighted average grant date fair value price
Unvested at beginning of year		-	$	-
Granted		780,100		7.15
Vested		-		-
Forfeited and cancelled		-		-
Unvested as of March 31, 2017		780,100	$	7.15

Schedule of Fair Value of Equity Based Awards Using Black-Scholes Option Pricing Model

The fair value of equity-based awards was estimated using the Black-Scholes option-pricing model for all grants with the following underlying assumptions:

	Three months ended March 31,						Year ended December 31,
	2017			2016			2016
	Unaudited						Audited
Stock Option Plans
Expected term (years)	6.25				6.25		6.25
Expected volatility		59.15	%	59.80%-60.19%			58.40%-61.70%
Risk-free interest rate		2.23	%	1.52%-1.88%			1.23%-1.88%
Dividend yield		0	%		0	%		0	%
ESPP
Expected term (years)	0.5				-		0.42
Expected volatility		82.00	%		-			70.45	%
Risk-free interest rate		0.62	%		-			0.40	%
Dividend yield	0%				-		0%

Schedule of Non-cash Share-based Compensation Expense Related to Company's Equity-Based Awards

The total non-cash share-based compensation expense related to all of the Company’s equity-based awards recognized for the three months ended March 31, 2017 and 2016 and the year ended December 31, 2016 was:

	Three months ended March 31,				Year ended December 31,
	2017		2016		2016
	Unaudited				Audited
Cost of revenues	$	143	$	141	$	623
Research, development and clinical trials		862		763		3,155
Sales and marketing		655		1,290		5,111
General and administrative		2,901		3,262		12,552
Total share-based compensation expense	$	4,561	$	5,456	$	21,441